Regentis Biomaterials Shares Soar 850% After Canceling $10M Share Offering
RGNT•Regentis Biomaterials withdrew its Form F-1 registration statement, canceling a planned firm-commitment offering of 3.33 million shares at $3 each plus a 500,000-share over-allotment option. Shares surged more than 850% to an all-time high as its GelrinC Phase III trial exceeds 50% enrollment with European commercialization preparations underway.
1. Offering Withdrawal
Regentis Biomaterials filed to withdraw its Form F-1 registration statement, halting a firm-commitment public offering of 3.33 million ordinary shares at $3 each that would have raised about $10 million before expenses. The company had also granted underwriters a 45-day option to purchase up to 500,000 additional shares for over-allotments.
2. Stock Price Reaction
Following the withdrawal announcement, shares of Regentis Biomaterials jumped over 850%, marking the largest single-day gain in the company’s history and driving the stock to a fresh all-time high. Investor enthusiasm was fueled by the removal of potential dilution.
3. GelrinC Trial and Commercial Plans
Regentis is evaluating its lead hydrogel implant, GelrinC, in a Phase III knee cartilage regeneration trial, with more than half of the patient cohort already enrolled. The company is positioning GelrinC for potential European commercialization and eventual FDA submission upon trial completion.
